ArticleCureus2025
Rapidly Resolving Myositis Ossificans in an Adolescent Female.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myositis ossificans (MO) is a rare benign tumor characterized by heterotopic ossification of soft tissues. While the term "myositis" suggests that the lesion commonly affects muscles, it can also occur in rare locations such as tendons or subcutaneous tissues. MO is infrequent in children, primarily affecting young adults and adolescents. It presents distinct radiological and histological features. However, it is crucial to exclude malignancy when investigating heterotopic ossification. Surgical excision of the lesion following an appropriate biopsy is an option, but cases of self-limiting MO have been reported. We report a unique case of a 14-year-old girl who presented with painful restriction of movement in the lumbar and gluteal regions, without any history of trauma. The girl underwent thorough clinical and radiological investigations, with MRI revealing a circumscribed ossifying lesion measuring 3.8 × 2.3 cm in the gluteal subcutaneous area, lacking clear boundaries, with edema of the adjacent muscles. The lesion exhibited heterogeneous signal intensity and contrast enhancement, while 18F-FDG PET/CT revealed increased metabolic activity within the lesion. A US-guided needle biopsy was performed, confirming the diagnosis of MO with a typical zonal phenomenon. The girl was referred for surgical removal of the lesion within three months after the initial MRI. Upon re-evaluation, the mass was barely palpable, and subsequent MRI and CT scans showed a marked reduction in lesion size. We followed the patient, and in another three months, the mass had almost completely regressed. We aimed to report a unique case of an adolescent with an established diagnosis of MO, following appropriate radiological and histological evaluation. The rapid regression of the lesion suggests that MO can be managed conservatively in selected cases rather than through immediate surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.